Search NAGE
Niagen Bioscience, Inc.
Nasdaq · CIK 1386570
Last close2.79
Daily change+0.11 (4.10%)
10 Years gain-7.62%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
NAGE · STANDARD
SIC 2833 · Medicinal Chemicals & Botanical Products · Fiscal year end 1231
Fundamental
84.4Momentum
61.7Acceleration
37.0Confidence
91.0Annual Revenue16
Quarterly Revenue67
Annual CFO16
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth23.4 / 25
Quality19.4 / 25
Capital Efficiency18.9 / 20
Balance Sheet15.0 / 15
Shareholder Economics3.6 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 2.325 percentage points.
Operating leverageOperating margin improved by 2.3378 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Share count reductionDiluted share count declined 0.8747%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
ROIC declining · MEDIUMROIC declined by 1781.2741 percentage points.
Key Metrics
Revenue Growth TTM25.17%OK
Revenue CAGR 3Y21.56%OK
Gross Margin64.45%OK
Operating Margin7.67%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC117.43%OK
Incremental Operating Margin 3Y55.95%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.87%OK
SBC / Revenue5.29%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $129.42M | $83.19M | $16.28M | $13.50M | n/a | 64.28% | 12.58% | n/a | 233.21% | 85.44M |
| 2025 FY Dec 31, 2024 | $99.60M | $61.59M | $7.73M | $12.11M | n/a | 61.84% | 7.76% | n/a | 523.5% | 78.13M |
| 2024 FY Dec 31, 2023 | $83.57M | $50.78M | -$5.60M | $7.12M | n/a | 60.76% | -6.7% | n/a | -91.88% | 74.99M |
| 2023 FY Dec 31, 2022 | $72.05M | $42.80M | -$18.63M | -$15.10M | n/a | 59.4% | -25.85% | n/a | -247.75% | 69.73M |
| 2022 FY Dec 31, 2021 | $67.45M | $41.49M | -$27.07M | -$24.16M | n/a | 61.51% | -40.14% | n/a | -1,322.27% | 67.19M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $126.36M | sum latest 4 fiscal quarters Revenue | OK | 0001386570-26-000043, 0001386570-25-000020 |
| Revenue Growth TTM | 25.17% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001386570-26-000043, 0001386570-25-000020 |
| Revenue CAGR 3Y | 21.56% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001386570-26-000013 |
| Revenue CAGR 5Y | 16.91% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001386570-26-000013 |
| Gross Profit CAGR 3Y | 24.8% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001386570-26-000013 |
| Operating Income Growth | 80.01% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001386570-26-000043, 0001386570-25-000020 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 64.45% | Gross Profit / Revenue | OK | 0001386570-26-000043, 0001386570-25-000020 |
| Operating Margin | 7.67% | Operating Income / Revenue | OK | 0001386570-26-000043, 0001386570-25-000020 |
| ROIC | 117.43% | NOPAT / Average Invested Capital | OK | 0001386570-26-000043, 0001386570-25-000020 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001386570-26-000043 |
| Current Ratio | 6.5x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 5.29% | SBC / Revenue | OK | 0001386570-26-000043, 0001386570-25-000020 |
| Revenue per Diluted Share | $1.53 | Revenue / Diluted Shares | OK | 0001386570-26-000043, 0001386570-25-000020 |